Vinpocetine for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Vinpocetine for Health & Longevity

Created on 08/07/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Vinpocetine supports brain blood flow and may calm vessel inflammation. Older trials report modest cognitive signals mainly with circulatory brain impairment; healthy-brain enhancement remains thinly proven. Day-to-day tolerability at usual divided oral doses is generally favorable. Pregnancy is a firm exclusion; bleeding risk rises with anticoagulants or antiplatelets. U.S. product identity has been uneven. (Full Review)

Protocol

Standard oral range
15–60 mg/day
Almost always divided into three doses with meals (short half-life ~1–2.5 h)
Low maintenance dose
5 mg three times daily
15 mg/day total; mid-range often 10 mg three times daily; up to 20 mg three times daily in older dementia trials
Food
With meals
Breakfast, lunch, dinner; improves bioavailability and reduces GI irritation; evening dose may be moved earlier if insomnia appears
Time to effect
Brain Blood Flow
Days to weeks
Perfusion and subjective clear-headedness, when they occur
Cognitive Scales
Weeks to months
Cognitive-scale changes in trials; dementia studies rarely exceeded 6–12 months

Benefits

Contraindications
  • Pregnant women and those trying to conceive (absolute avoidance)
  • Breastfeeding individuals
  • Active major bleeding, recent hemorrhagic stroke, or untreated bleeding disorders
  • Acute hypertensive crisis or unstable cardiac conditions until stabilized
  • Known severe hypersensitivity to vinpocetine or vinca-related compounds
    •
Key Interactions
  • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran)
  • Antiplatelet agents (aspirin, clopidogrel, ticagrelor, prasugrel)
  • Blood-pressure–lowering agents (ACE inhibitors e.g. lisinopril, ramipril; ARBs e.g. losartan, valsartan; calcium-channel blockers e.g. amlodipine; beta-blockers e.g. metoprolol; diuretics e.g. hydrochlorothiazide)
  • Supplements with anticoagulant/antiplatelet effects (high-dose fish oil, ginkgo, garlic, high-dose vitamin E)
  • P-gp substrates (e.g., certain chemotherapeutic agents, digoxin in some contexts)
  • CYP3A4 / CYP2D6 substrates (e.g., midazolam, simvastatin; metoprolol, codeine)
    •

Risk & Side Effects

  • High: Fetal harm and pregnancy loss risk
    •
  • Medium: Gastrointestinal discomfort; headache, dizziness, flushing, and transient hypotension; increased bleeding tendency with antithrombotic drugs
    •
  • Low: Sleep disturbance, nervousness, or drowsiness; transient tachycardia or cardiac sensation; mild reductions in blood pressure or blood glucose with prolonged use
    •
  • Speculative: Hematologic effects; long-term unknowns at supplement doses
    •

Monitoring

Marker Target Why
Blood pressure (seated & standing) Individualized; avoid symptomatic orthostasis Detect vasodilatory dizziness/hypotension
INR (if on warfarin) Therapeutic range set by clinician Warfarin interaction / bleed risk
CBC Within lab reference Rare hematologic reports
Fasting glucose / HbA1c Functional targets per metabolic plan Mild glucose shifts with prolonged use; vascular risk control
Lipid panel ApoB and LDL optimized per personal risk Foundational cerebrovascular risk

Cadence: Blood pressure and symptoms at 1–2 weeks; clinical check at 4–8 weeks; every 6–12 months if continued; INR recheck within 3–7 days if on warfarin

Qualitative Assessment

  • Subjective mental clarity, word-finding, and attention under normal workload
  • Headache frequency/intensity and flushing
  • Dizziness on standing; exercise tolerance
  • Sleep onset and continuity
  • Bruising or bleeding gums (especially if on antithrombotics)
  • GI comfort with mealtime dosing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.